ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Vorinostat (MK0683), an HDAC Inhibitor, in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma (0683-095 AMJ)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00773838
Recruitment Status : Completed
First Posted : October 16, 2008
Last Update Posted : April 25, 2016
Sponsor:
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.